

What Trump's FTC Picks Mean for Bio-Pharma Dealmaking and PBMs

MEDIA MENTIONS | LESS THAN 1 MIN READ

December 16, 2024


By: Jared Whitlock

Endpoints News

Axinn managing partner Jeny Maier was quoted in the *Endpoint News* article, "What Trump's FTC Picks Mean for Bio-Pharma Dealmaking and PBMs."

Click [here](#) to access the publication. A subscription is required.

Related People



Jeny M. Maier

Related Services

Antitrust

To subscribe to our publications, [click here](#).

Featured Insights

- American Bar Association 2025 Asia-Pacific Conference
SPEAKING ENGAGEMENT ANTITRUST
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference
SPONSORSHIP ANTITRUST
- GCR Live: Law Leaders Global 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Corporate Counsel Retreat 2025
SPONSORSHIP ANTITRUST
- Forecasting Health Care Antitrust Under a Second Trump Administration
PODCAST ANTITRUST
- GCR 100 2025 Ranks Axinn Antitrust Group in Top Categories
AWARDS & RECOGNITIONS ANTITRUST
- Capitol Forum Health Care Competition Conference 2024
SPEAKING ENGAGEMENT ANTITRUST
- Ethical Considerations for Cybersecurity, IP Transactions and Avoiding USPTO Sanctions (EIP241212)
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Albertsons Ends Merger Deal, Accuses Kroger of 'Self-Serving Conduct'
MEDIA MENTIONS ANTITRUST

- Denise Plunkett Named a 2024 Notable Leader in Accounting, Consulting & Law by Crain's New York Business

AWARDS & RECOGNITIONS

LITIGATION & TRIALS

© 2024 Axinn, Veltrop & Harkrider LLP. All Rights Reserved